Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Receivables: 2020-2025

Historic Change in Receivables for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $25.8 million.

  • Legend Biotech's Change in Receivables rose 108.67% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72,000, marking a year-over-year decrease of 125.17%. This contributed to the annual value of $93.8 million for FY2024, which is 194.72% up from last year.
  • Latest data reveals that Legend Biotech reported Change in Receivables of $25.8 million as of Q3 2025, which was up 198.44% from -$26.2 million recorded in Q2 2025.
  • Legend Biotech's Change in Receivables' 5-year high stood at $96.7 million during Q1 2024, with a 5-year trough of -$99.0 million in Q4 2023.
  • Over the past 3 years, Legend Biotech's median Change in Receivables value was $34,000 (recorded in 2023), while the average stood at $25,818.
  • As far as peak fluctuations go, Legend Biotech's Change in Receivables plummeted by 319,416.13% in 2023, and later surged by 284,411.76% in 2024.
  • Legend Biotech's Change in Receivables (Quarterly) stood at -$48.9 million in 2021, then soared by 99.94% to -$31,000 in 2022, then crashed by 319,416.13% to -$99.0 million in 2023, then surged by 94.36% to -$5.6 million in 2024, then soared by 108.67% to $25.8 million in 2025.
  • Its last three reported values are $25.8 million in Q3 2025, -$26.2 million for Q2 2025, and $5.9 million during Q1 2025.